# UX discovery loop — validation report

## Task
- Contract: task-contract.md; bounded ledger: cycle-ledger.md.
- Date: 2026-10-04.
- Application baseline: 750b0a03 (application f4a31fe).
- Final application/test candidate: 347b490128564e194dbe907cbee8e4e2fd30e295; application unchanged from ceafb0ee.
- Authorized destination: https://github.com/l2v-hub/ClinicOS, branch codex/ux-discovery-loop; frontend publication to the existing ClinicOS Vercel project. Backend/database release outside this contract.

## Implementation Summary
One therapeutic plan combines the dose calendar and collapsible prescription/programming details. All prescription fields, document links, role-gated actions and legacy direct targets remain available. Fixed invalid quantity drafts, unit-change visibility, stale calendar refresh, PRN panels crossing dates, Rome day defaults, duplicated allergy outputs, doubled module counts, partial urgency counts, malformed handover response handling, misleading legacy urgency wording and hash/history/reload navigation.

The last cycle compacts operator dashboard KPIs and due-dose rows. Validated patient location uses one label, preserving the distinction between unassigned and unavailable; compatibility sources retain their original location details. Clinical priority and treatment logic were not changed.

## Acceptance Criteria Result
| AC | Result | Evidence |
|---|---|---|
| AC1 | PASS | Independent discovery/default-therapy runtime; live single plan and exact dose target |
| AC2 | PASS |130focused tests; interaction/failure/role regressions |
| AC3 | PASS | Independent real App checks at390/768/1074/1395 plus1150; live no overflow |
| AC4 | PASS | Unavailable shared acknowledgements/counts explicit; no invented success or receipt |
| AC5 | PASS | Exactly10 cycles; independent QA five phases READY FOR CODEX QA |
| AC6 | PASS | Scoped TypeScript/Vite/tests, authorized remote push, Vercel READY and live verification |
| AC7 | PASS | Independent density-runtime: full content, no clipping/overflow, controls48px;1150 KPI118→64px, synthetic row234→146px; live rows126/126/146px |

## Test Results
| Test | Result | Evidence |
|---|---|---|
| Discovery unit/regression | PASS65 | test-results/discovery-focused.txt |
| Prior dashboard/patient regressions | PASS65 | test-results/focused.txt |
| Frontend build (TypeScript+Vite) | PASS | test-results/build.txt;662modules |
| New dashboard runtime | PASS | test-results/density-runtime.json; five widths, full fields, correct therapy action, zero clinical writes/errors |
| Wider interaction browser suites | PASS11+17groups | final-independent-qa/test-results/discovery-runtime.json and runtime.json |
| Shared persistence | Synthetic API only | failure/success/reload mocked; no claim of deployed backend acknowledgement support |
| API/DB/Agnos/voice/OCR | No changes | outside scoped frontend task |
| Independent security/QA | PASS five phases | final-independent-qa/validation-report.md; READY FOR CODEX QA |

## Runtime Evidence
Local screenshots, trace, video and HTML reports use synthetic fixtures. Dashboard before/after measures reference immutable source9ca67e3 and final candidate. Binary artifacts remain local and are excluded from publication. No live clinical fields are exported in the release receipt.

## Release Evidence
Git push of347b4901 confirmed remotely. Vercel deploymentdpl_98hFoo21QnMbG713b3GV22CVZmGH READY, aliashttps://clinicos-eosin.vercel.app,662modules. Live bundle/assets/index-B4GWTG3B.js verified. At1150px: all KPI64px, rows126/126/146px, controls48px, no document overflow/module errors/new console errors. Dose action opens selected calendar dose/panel; one therapy plan and one allergy band, no duplicate header allergy. No clinical writes; user's in-progress form was preserved in its original tab. Temporary viewport restored.

QA input fingerprint matched all816inputs byte-for-byte after aligning68EOL-only files; no Git application/test diff. Full manifest is final-independent-qa/source-receipt.json; authorization/side-effect envelope in release-policy.md; sanitized production receipt in release-receipt.json. Subsequent report-only commit does not alter reviewed application/build inputs.

## Residual Risks
Bounded discovery does not establish absence of all bugs. The deployed legacy backend lacks shared Ho capito/exact urgency capabilities: the UI continues to report unavailable/unknown. No server or database deployment occurred. Only scoped test suites are claimed; unrelated historical full-suite failures are not represented as passing. Vite's existing chunk-size advisory and Node's harness shell deprecation warning remain non-fatal.

## Final Decision
CLOSED — VERIFIED
